Back

Glenmark Pharmaceuticals Launches Generic Inlyta Tablets in US

Glenmark's US arm launched Axitinib Tablets, 1 mg and 5 mg, an authorized generic of Pfizer's INLYTA.

Glenmark Pharmaceuticals: Glenmark logo over a photo of a scientist working in a lab

Key Takeaways

  • Glenmark Pharmaceuticals Inc., USA launched Axitinib Tablets, 1 mg and 5 mg, on November 16, 2026.
  • The product is an authorized generic of Pfizer's INLYTA, used for advanced renal cell carcinoma.
  • IQVIA data cited by Glenmark puts US INLYTA sales at about $538.4 million for the 12 months ending September 2026.
  • Glenmark ships its US medicines from its Allentown hub to 321 locations in 43 states.
  • Glenmark has not disclosed expected revenue from the launch.
Table of Contents 5 sections
  1. Glenmark's axitinib launch at a glance
  2. How axitinib fits Glenmark's US business
  3. Marc Kikuchi on access to affordable medicines
  4. Where Glenmark's US oncology range stands after the launch
  5. FAQs

Glenmark Pharmaceuticals said on November 16, 2026, that its US subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Axitinib Tablets in 1 mg and 5 mg strengths in the United States. The company said the product is an authorized generic version of INLYTA (axitinib) tablets, a registered trademark of Pfizer Inc.

INLYTA is used to treat advanced renal cell carcinoma, a type of kidney cancer. According to IQVIA sales data for the 12 months ending September 2026, as cited by Glenmark, US annual sales of INLYTA tablets were about $538.4 million. That figure is the US sales of the reference brand, not Glenmark's own sales from the new product.

Glenmark's axitinib launch at a glance

DetailValue
CompanyGlenmark Pharmaceuticals Inc., USA, the US subsidiary of Glenmark Pharmaceuticals Ltd.
ProductAxitinib Tablets, 1 mg and 5 mg
TypeAuthorized generic of INLYTA (axitinib) tablets
Brand ownerINLYTA is a registered trademark of Pfizer Inc.
Used forAdvanced renal cell carcinoma, a type of kidney cancer
MarketUnited States
US sales of INLYTAAbout $538.4 million in the 12 months ending September 2026, per IQVIA data cited by Glenmark
AnnouncedNovember 16, 2026

How axitinib fits Glenmark's US business

Glenmark Pharmaceuticals is a Mumbai-based pharmaceutical company listed on the BSE and NSE. It sells branded, generic, innovative and consumer health products in more than 80 countries, with a focus on respiratory, dermatology and oncology.

In the US, Glenmark ships prescription and over-the-counter medicines from a distribution center in Allentown, Pennsylvania, which it inaugurated in October 2026. The company said the roughly 160,000-square-foot facility is its sole US distribution hub and serves 321 locations in 43 states with 45 employees. For the quarter ended September 30, 2026, Glenmark reported consolidated revenue of about Rs 4,247 crore and adjusted profit after tax of about Rs 485 crore.

WhenWhat happened
October 2026Glenmark inaugurated its Allentown, Pennsylvania distribution center, its sole US distribution hub
November 5, 2026Glenmark reported Q2 FY27 consolidated revenue of about Rs 4,247 crore
November 16, 2026Glenmark Pharmaceuticals Inc., USA launched Axitinib Tablets, 1 mg and 5 mg

Marc Kikuchi on access to affordable medicines

"The launch of Axitinib Tablets reinforces Glenmark's commitment to expanding access to quality, affordable medicines for patients in the United States."

Marc Kikuchi, President and Business Head, North America, Glenmark

Kikuchi also said that by adding the product to its portfolio, Glenmark continues to strengthen its focus on the evolving needs of patients and healthcare providers. The company has not disclosed how much revenue it expects from the launch.

Where Glenmark's US oncology range stands after the launch

With this launch, Glenmark Pharmaceuticals Inc., USA now sells Axitinib Tablets in 1 mg and 5 mg strengths as an authorized generic of Pfizer's INLYTA. The reference brand recorded about $538.4 million in US sales in the 12 months ending September 2026, according to IQVIA data cited by the company. Glenmark ships its US medicines from its Allentown hub to 321 locations in 43 states.

More news

Join Us Add as preferred source
Share

Frequently Asked Questions

What did Glenmark Pharmaceuticals launch in the US?

Glenmark Pharmaceuticals, through its US subsidiary Glenmark Pharmaceuticals Inc., USA, launched Axitinib Tablets in 1 mg and 5 mg strengths on November 16, 2026.

What is Glenmark's axitinib product a generic of?

Glenmark Pharmaceuticals said its Axitinib Tablets are an authorized generic version of INLYTA (axitinib) tablets, a registered trademark of Pfizer Inc.

What is INLYTA used to treat?

INLYTA, which Glenmark Pharmaceuticals now offers as an authorized generic, is used to treat advanced renal cell carcinoma, a type of kidney cancer.

How big is the US market for INLYTA?

Glenmark Pharmaceuticals cited IQVIA data showing US annual sales of INLYTA tablets of about $538.4 million in the 12 months ending September 2026.

How many strengths of axitinib did Glenmark launch?

Glenmark Pharmaceuticals launched Axitinib Tablets in two strengths, 1 mg and 5 mg.

How much revenue does Glenmark expect from axitinib?

Glenmark Pharmaceuticals has not disclosed how much revenue it expects from the axitinib launch.

Who announced the axitinib launch for Glenmark?

Marc Kikuchi, President and Business Head, North America, spoke for Glenmark Pharmaceuticals on the axitinib launch.

What did Marc Kikuchi say about the launch?

Marc Kikuchi said the launch reinforces Glenmark Pharmaceuticals' commitment to expanding access to quality, affordable medicines for patients in the United States.

Which Glenmark company made the launch?

The launch was made by Glenmark Pharmaceuticals Inc., USA, the US subsidiary of Glenmark Pharmaceuticals Ltd.

How does Glenmark distribute medicines in the US?

Glenmark Pharmaceuticals said its Allentown, Pennsylvania distribution center, inaugurated in October 2026, is its sole US distribution hub and serves 321 locations in 43 states.

What is Glenmark Pharmaceuticals?

Glenmark Pharmaceuticals is a Mumbai-based pharmaceutical company with a presence in more than 80 countries and a focus on respiratory, dermatology and oncology.

What was Glenmark's revenue in Q2 FY27?

Glenmark Pharmaceuticals reported consolidated revenue of about Rs 4,247 crore for the quarter ended September 30, 2026.

More in Business